Clinical Feasibility and Treatment Outcomes With Unselected Autologous Tumor Infiltrating Lymphocyte Therapy in Patients With Advanced Cutaneous Melanoma

Robert E. Hawkins,¹⁻³ Yizhou Jiang,¹ Paul C. Lorigan,² Fiona C. Thistlethwaite,^{2,3} Manon Pillai,² Martine Thomas,¹ Natalia Kirillova,¹ John S. Bridgeman,¹ Gray Kueberuwa,¹ Ryan D. Guest,¹ Zachary J. Roberts¹

¹Instil Bio, Inc., Dallas, TX; ²The Christie, NHS Foundation Trust, Manchester, United Kingdom; ³University of Manchester, Manchester, United Kingdom

BACKGROUND

- A minority of patients with advanced melanoma achieve long-term survival with immunotherapy, and those who relapse following immune checkpoint inhibition (ICI) and, if BRAF-mutated, BRAF inhibition have limited treatment options
- The intrinsic antitumor activity and broad T-cell receptor repertoire of unselected autologous tumor infiltrating lymphocytes (TILs) may provide advantages over other treatments in solid tumors, including ICI-refractory melanoma

TIL therapy has demonstrated durable complete remissions in patients with melanoma, with an estimated 41% objective response rate in advanced cutaneous melanoma¹

METHODS

- This is a retrospective analysis of a single-center experience of TILs for compassionate use treatment of advanced cutaneous melanoma
- Unselected autologous TILs derived from digested tumor tissue were manufactured under a Medicines and Healthcare Products Regulatory Agency Manufacturing Specials license (Figure 1)
- Twenty-one patients with advanced cutaneous melanoma and no standard of care treatment options received non-myeloablative lymphodepleting chemotherapy (cyclophosphamide 60 mg/kg/day × 2 days, fludarabine 25 mg/m²/day × 5 days [Cy/Flu]) followed by TIL infusion and post-TIL high-dose (HD) interleukin-2 (IL-2) (600,000-720,000 IU/kg) on a compassionate use basis (Figure 1)
- Patients were hospitalized for treatment
- Efficacy for 15 of 21 patients was locally assessed by computed tomography (CT)/magnetic resonance imaging (MRI) in accordance with Response Evaluation in Solid Tumors (RECIST) version 1.1. Efficacy for the remaining 6 patients was assessed using non-RECIST 1.1 imaging (eg, positron emission tomography) and clinical monitoring (eg, history and physical examination, laboratory assessments)
- Clinically significant adverse events (AEs) with onset post-TIL infusion were reported during the hospitalization period for all treated patients
- Data cutoff date: December 31, 2019

Figure 1. Tissue Procurement and Manufacturing



IL-2, interleukin-2; IV, intravenous; REP, rapid expansion protocol; TIL, tumor infiltrating lymphocyte

Table 1. Patient Selection Guidelines

 Histologically confirmed malignant melanoma with confirmed evidence of progressive metastatic disease Satisfactory hematological and biochemical indices Adequate cardiac function Suitable fitness for all planned treatments and procedures (including surgery for TIL harvest, lymphodepleting chemotherapy, TILs, and IL-2) A metastatic site that could be excised to obtain a specimen of at least 1 cm³. For lymph nodes, these must have been >2 cm³ Measurable/evaluable disease after the surgical resection No standard of care treatment options Prior allogeneic transplant Symptomatic brain metastasis measuring ≥10 mm in diameter Lymphotoxic therapy such as chemotherapy, HD steroids, or other immunosuppressive therapy within 4 weeks of harvesting Concurrent serious infection within 28 days prior to treatment Steroid use ≤3 weeks before treatment, except for physiological replacement doses of steroids 	Should Have	Should Not Have
	 Histologically confirmed malignant melanoma with confirmed evidence of progressive metastatic disease Satisfactory hematological and biochemical indices Adequate cardiac function Suitable fitness for all planned treatments and procedures (including surgery for TIL harvest, lymphodepleting chemotherapy, TILs, and IL-2) A metastatic site that could be excised to obtain a specimen of at least 1 cm³. For lymph nodes, these must have been >2 cm³ Measurable/evaluable disease after the surgical resection No standard of care treatment options 	 Prior allogeneic transplant Symptomatic brain metastasis measuring ≥10 mm in diameter Lymphotoxic therapy such as chemotherapy, HD steroids, or other immunosuppressive therapy within 4 weeks of harvesting Concurrent serious infection within 28 days prior to treatment Steroid use ≤3 weeks before treatment, except for physiological replacement doses of steroids

HD, high dose; IL-2, interleukin-2; TIL, tumor infiltrating lymphocyte

Presented at the American Association for Cancer Research (AACR) Virtual Annual Meeting, April 10-15, 2021.

RESULTS

Table 2. Treatment Exposure

Treatment Exposure	All Treated Patients (N=21)
Received fludarabine lymphodepletion, n (%)	21 (100)
Received cyclophosphamide lymphodepletion, ^a n (%)	21 (100)
Total TIL cells infused (×10 ⁹), median (range)	32 (8 – 63)
Number of IL-2 doses (n), median (range)	8 (4 – 11)

IL-2, interleukin-2; TIL, tumor infiltrating lymphocyte ^a All but 1 patient received planned doses of cyclophosphamide/fludarabine lymphodepleting chemotherapy prior to the TIL infusion. One patient received slightly reduced doses of cyclophosphamide due to prior neutropenia, generally deteriorating health, and an elevated risk of atrial fibrillation.

 Between October 2011 and August 2019, 21 patients with advanced cutaneous melanoma were treated

• Median duration of follow-up: 52.2 months

Table 3. Demographics and Baseline Characteristics

	Imaging Evaluable Set (n=15)	All Treated Patients (N=21)
Age (y), median (range)	54 (16 – 68)	45 (16 – 68)
Male, n (%)	11 (73)	15 (71)
Stage IV, n (%)	15 (100)	21 (100)
Disease sites, median (range) M1c disease, n (%) M1d disease, n (%)	4 (2 – 10) 10 (67) 5 (33)	4 (2 – 10) 14 (67) 7 (33)
Tumor burden (mm), ^a median (range)	123 (29 – 281)	100 (13 – 281) ^b
LDH, n (%) >ULN to ≤2 × ULN >2 × ULN	3 (20) 3 (20)	7 (33) 3 (14)
Prior systemic regimens (n), mean (range) Checkpoint inhibitor, n (%) PD-1 inhibitor CTLA-4 inhibitor Dual PD-1/CTLA-4 inhibitor relapsed/refractory	3 (1 – 5) 14 (93) 9 (60) 14 (93) 9 (60)	3 (1 – 9) 19 (91) 12 (57) 19 (91) 12 (57)
BRAF-mutated patients, n (%)	7 (47)	11 (52)
BRAF inhibitor ± MEK inhibitor	7 (47)	11 (52)

BRAF, B-raf proto-oncogene; CTLA-4, cytotoxic T-lymphocyte-associated protein 4; LDH, lactate dehydrogenase; PD-1, programmed cell death protein 1; RECIST, Response Evaluation in Solid Tumors; ULN, upper limit of normal. ^a Target lesions sum of diameters (local assessment per RECIST 1.1). ^b 20 of 21 patients had tumor burden data available at baseline.

Table 4. Summary of Safety

TEAEs Post-TIL Infusion ≥15%, n (%)	Any Grade (N=21)
Thrombocytopenia	13 (62)
Pyrexia	12 (57)
Rigors	9 (43)
Neutropenia	6 (29)
Tachycardia	6 (29)
Pulmonary edema	5 (24)
Vascular Leak	5 (24)
Rash	4 (19)

TEAE, treatment-emergent adverse event; TIL, tumor infiltrating lymphocyte.

No grade 5 treatment-emergent AEs (TEAEs) were observed

- 10 patients died \geq 90 days after TIL infusion and prior to data cutoff
- 4 due to progressive disease (PD)
- 1 possibly due to AE caused by subsequent anticancer therapy
- 5 with documented PD prior to death but specific cause of death not available

Cytopenias

- Onset: \approx -7 to 0 days (lymphodepletion)

- Nadir: \approx 1 to 4 days (post-TIL)
- Recovery: \approx 7 days (post-TIL)

Table 5 Best Overall Response

Response	Imaging Evaluable Set ^a (n=15)	All Treated Patients ^b (N=21)		
Best overall response (CR + PR), n (%)	8 (53)	14 (67)		
CR	2 (13)	4 (19)		
PR	6 (40)	10 (48)		
Stable disease, n (%)	3 (20)	4 (19)		
Progressive disease, n (%)	4 (27)	3 (14)		
Disease control rate (CR + PR + SD), n (%)	11 (73)	18 (86)		
Median time to response, months	1.7	1.7		

Figure 2. Overall Survival

dabrafenib to prevent tumor flare.



Figure 4. Time to Response and Overall Survival in Responding Patients (n=14)

	-
Patient	Prior Checkpoin Inhibitor
1 ^a	No
2	Ipi
3	No
4 ^b	Ipi
5	Ipi and pembro
6	Ipi and nivo
7 ^b	Ipi and nivo
8	Ipi and pembro
9	Ipi
10 ^a	Ipi and nivo
11	Ipi and pembro
12ª	Ipi
13	Ipi, nivo, and pem
14	Ipi

BRAF, B-raf proto-oncogene; CR, complete remission; HD, high dose; IL-2, interleukin-2; Ipi, ipilimumab; MEK, mitogen-activated protein kinase; nivo, nivolumab; PD, progressive disease; PD-1, programmed cell death protein 1; pembro, pembrolizumab; PR, partial remission; TIL, tumor infiltrating lymphocyte Patient 1 received a checkpoint inhibitor at the time of disease progression; patients 10 and 12 received checkpoint inhibitor and HD IL-2, respectively, prior to documented disease progression. ^o Patients 4 and 7 had unequivocally BRAF+MEK-refractory melanoma immediately prior to TIL treatment but were continued on dabrafenib, with brief interruptions for tumor harvest and TIL infusion, to prevent tumor flare upon discontinuation. Patient 4 was treated with dabrafenib for 3 months following TIL infusion, at which point the dabrafenib was stopped. Patient 7 achieved a PR that lasted approximately 14 months from TIL infusion during which time dabrafenib was continued.

• With a median follow-up of 52.2 months, 5/21 (24%) had durable ongoing responses (>30 months post-TIL infusion)

 Responses were generally consistent across subgroups, including age, number of disease sites, number of prior lines of therapy, prior BRAF inhibitor, prior PD-1 inhibitor, baseline brain metastasis, and baseline tumor burden

a Imaging evaluable set includes all treated patients with a baseline CT or MRI-based disease assessment and at least 1 CT or MRI-based disease assessment per RECIST 1.1 prior to any subsequent anticancer therapy. Confirmation of response was not required.

e Responders include 2 patients with dabrafenib + MEK inhibitor-refractory disease whose disease was unequivocally progressing on the combination therapy prior to TIL and who received postinfusion

l						0						CR/I	PR (n	=8)	
NR (n=7) Median (95% CI) CR/PR: NE (10.2 – NR: 6.5 (3.4 – NE)) — NE) E)						
15	20	25	30	35	40 Time	45 (Mo	50 nths)	55	60	65	70	75	80	85	90
5 (1) 2 (0)	4 (1) 2 (0)	4 (1) 2 (0)	4 (1) 2 (0)	3 (2) 2 (0)	3 (2) 2 (0)	2 (3) 1 (1)	2 (3) 1 (1)	2 (3) 1 (1)	2 (3) 0 (2)	2 (3) 0 (2)	2 (3) 0 (2)	2 (3) 0 (2)	2 (3) 0 (2)	2 (3) 0 (2)	0 (5) 0 (2)

Figure 3. Depth of Responses in Imaging Evaluable Set (n=14)^a





• All patients achieving a complete remission (CR) remained alive and disease free as of data cutoff

presented in the plot.

InstilBio

CASE STUDY: SUCCESSFUL TREATMENT OF BRAIN METASTASES

- CR PR SD PD

- measures reported (progression determined by observation of new lesions) and hence was not

- Patient and Disease Characteristics 16-year-old male with BRAF-mutated melanoma
- Extensive mediastinal disease and brain metastases
- Bulky disease (sum of longest diameters 103 mm)
- Prior Treatment History
- Relapsed/refractory to 3 prior lines of therapy, including ipilimumab, a CTLA-4 inhibitor, and dabrafenib, a BRAF inhibitor
- Response to TIL Therapy - Rapid reduction in his disease burden observed at 6 weeks Partial remission achieved at 3 months
- CR determined by clinical review at 56 months and confirmed with CT/ MRI at month 60 post-TIL therapy Ongoing CR at 85 months (>7 years) post-TIL therapy

• TEAEs

- Expected HD IL-2—related toxicities were observed
- Overall, 8 IL-2 doses were administered with tachycardia, fever, and cardiovascular instability observed with each dose. No evidence of infection

6 weeks

- Seizure in the setting of high fever and tachycardia/shortness of breath after dose 6, which resolved spontaneously; 7th dose of IL-2 delayed, prophylactic levetiracetam administered, and no further seizure events observed
- Symptomatic cough/shortness of breath due to disease, present prior to treatment, worsened during IL-2, and subsequently improved after IL-2 stopped
- Neutropenia from days 1 to 6; no platelet support required

CONCLUSIONS

- TIL products made from digested tumors demonstrated high overall and CR rates in this retrospective analysis of a compassionate use case series conducted at the Christie Hospital in Manchester, United Kingdom
- AEs were consistent with the established safety profile¹ of Cy/Flu+TIL+IL-2 for treatment of advanced melanoma
- Autologous TIL manufacturing and administration is feasible and may offer significant clinical benefit to patients with checkpoint inhibitor-and, if applicable, BRAF±MEK inhibitor-refractory melanoma
- Additional process updates, including cryopreservation of digested tumor and process closure, have been implemented to improve the robustness, reproducibility, and scalability of the complex TIL manufacturing process to enable multicenter clinical trials with centralized manufacturing
- Results of this retrospective analysis should be interpreted with caution; further prospective clinical trials are warranted
- DELTA-1, a global phase 2 clinical trial of this therapy in patients with advanced melanoma is planned for 2021 (EudraCT 2020-003862-37)

REFERENCE

1. Dafni U, et al. Ann Oncol. 2019;30(12):1902-1913.

ACKNOWLEDGMENTS

- We would like to thank all the staff within The Christie NHS Foundation Trust and The Christie Clinic who worked tirelessly to provide high-quality care to all the patients in this report
- Medical writing support was provided by Christopher Waldapfel, PharmD of Instil Bio and Jennifer Leslie, PhD, of Nexus GG Science with funding from Instil Bio

DISCLOSURES

REH: Instil Bio (UK) Ltd., Manchester, United Kingdom; Cellular Therapeutics/Immetacyte Ltd, Manchester, United Kingdom; The Christie Hospital, Manchester, United Kingdom; The University of Manchester, Manchester, United Kingdom. YJ: Instil Bio, Inc, Tarzana, CA. PCL: The Christie Hospital, Manchester, United Kingdom; The University of Manchester, Manchester, United Kingdom. FCT: Innovate Manchester Advanced Therapy Centre Hub (iMATCH); Standard Approach to atMP tissue colLEction (SAMPLE) Project; Achilles Therapeutics Ltd, London United Kingdom. MP: The Christie Hospital, Manchester, United Kingdom; The University of Manchester, Manchester, United Kingdom. MT: Instil Bio (UK) Ltd., Manchester, United Kingdom. NK: Immetacyte Ltd, Manchester, United Kingdom. JSB: Instil Bio, Inc, Tarzana, CA. GK: Instil Bio, Inc, Tarzana, CA. RDG: Instil Bio, Inc, Tarzana, CA. ZJR: Instil Bio, Inc., Tarzana, CA.



Copies of this poster obtained through Quick Response (QR) Code are for personal use only and may not be reproduced without permissi from the author of this poster.

Ongoing Complete Remission >7 Years

12 months

Ongoing Complete Remission >7 Years



6 weeks l

5 years